Top of the morning to you, and a fine one it is. A shimmering sun and deliciously cool breeze are enveloping the Pharmalot campus, where one short person is sleeping in, another has left for gainful employment, and our official mascot is sniffing about. All of which is to say that conditions are just right for attacking our ever-growing to-do list. Perhaps you can relate to this task. If so, fire up your coffee kettle and join us for a cup of stimulation. Meanwhile, here are some tidbits to help you along. Hope you conquer the world today. …

President Trump is considering a sweeping executive order that would cut prices on virtually all brand-name medicines sold to Medicare and other government programs, according to Reuters. The order under discussion would be much broader than a previously disclosed proposal to lower prices on Part B drugs by tying prices to lower costs in other countries. The administration is now looking at ways to use this or a similar method to lower prices in Part D.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy